-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nitronazine in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nitronazine in Type 2 Diabetes report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nitronazine in Type 2 Diabetes Drug Details: Nitronazine is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nitronazine in Acute Ischemic Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nitronazine in Acute Ischemic Stroke report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nitronazine in Acute Ischemic Stroke Drug Details: Nitronazine is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nitronazine in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nitronazine in Amyotrophic Lateral Sclerosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nitronazine in Amyotrophic Lateral Sclerosis Drug Details: Nitronazine is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nitronazine in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nitronazine in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nitronazine in Type 2 Diabetes Drug Details: Nitronazine is under development for...
-
Product Insights
NewMyocardial Ischemia – Drugs In Development, 2024
Empower your strategies with our Myocardial Ischemia – Drugs In Development, 2024 report and make more profitable business decisions. Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris); neck or jaw pain; shoulder or arm pain; clammy skin; shortness of breath; and nausea and vomiting. Myocardial ischemia can be caused by conditions such as...
-
Product Insights
NewAlport Syndrome – Drugs In Development, 2024
Empower your strategies with our Alport Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Alport syndrome is a genetic disorder characterized by glomerulonephritis, end-stage kidney disease, and hearing loss. It is caused by an inherited defect in type IV collagen—a structural material that is needed for the normal function of different parts of the body. Since type IV collagen is found in the ears, eyes, and kidneys, this explains why Alport syndrome affects different seemingly unrelated...
-
Product Insights
NewVascular Dementias – Drugs In Development, 2024
Empower your strategies with our Vascular Dementias – Drugs In Development, 2024 report and make more profitable business decisions. Vascular dementia (VaD) is dementia caused by problems in the blood supply to the brain, resulting from a cerebrovascular disease. Restricted blood supply (ischemia) leads to cell and tissue death in the affected region, known as an infarct. Vascular dementia can be caused by ischemic or hemorrhagic infarcts affecting multiple brain areas, including the anterior cerebral artery territory, the parietal lobes, or...
-
Product Insights
NewPulmonary Arterial Hypertension – Drugs In Development, 2024
Empower your strategies with our Pulmonary Arterial Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea, and other diseases, including congenital heart disease,...
-
Product Insights
NewAcute Ischemic Stroke – Drugs In Development, 2024
Empower your strategies with our Acute Ischemic Stroke – Drugs In Development, 2024 report and make more profitable business decisions. An acute ischemic stroke occurs when a clot blocks a brain blood vessel, depriving it of oxygen. Symptoms, like numbness, confusion, or difficulty speaking, arise suddenly. Immediate medical attention is crucial. Treatment focuses on restoring blood flow, often with clot-dissolving drugs or a thrombectomy. Recovery varies; rehabilitation helps regain lost abilities. Lifestyle changes and medication may prevent future strokes. Early recognition...